News
-
-
-
-
PRESS RELEASE
Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
Moderna, Inc. will host a live conference call and webcast on August 1, 2024, reporting its second quarter financial results and giving a corporate update. Moderna leads in mRNA medicine, developing treatments and vaccines for various diseases -
-
-
PRESS RELEASE
Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
Moderna, Inc. awarded $176 million to accelerate mRNA-based pandemic influenza vaccine development through a Consortium funded by BARDA. Collaboration aims to enhance global public health preparedness -
-
-
PRESS RELEASE
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
Moderna, Inc. receives positive opinion from EMA CHMP for mRESVIA mRNA-1345 vaccine for RSV in adults aged 60+. The decision from the European Commission is awaited
